Roche (RHHBY) said that it has received CE Mark approval for the VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx, enabling the identification of metastatic breast cancer patients with low HER2 expression who may benefit from ENHERTU...

Ibex: NHS Expands Access to Ibex’s Galen™ Breast and Galen™ Prostate Solutions to 25 Trusts Across the UK Following PathLAKE Plus Consortium Bid Wins Tel Aviv, Israel – March 7, 2023 – Ibex Medical Analytics (Ibex), the leader...

Ibex: Pathology Diagnostics Platform Meets Safety, Quality and Performance Criteria Under EU's New In Vitro Diagnostic Medical Devices Regulation. TEL AVIV, Israel, Feb. 9, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in...

In recent years, artificial intelligence developers have changed the face of medicine with algorithms capable of detecting the earliest signs of cancer. Owkin, meanwhile, is taking a slightly different approach with its own cancer-spotting...

Ibex: Latest version of Galen™ transforms diagnosis of prostate, breast and gastric cancer and includes expanded detection, user-interface, and workflow integration capabilities   Tel Aviv, Israel, September 4, 2022 – Ibex Medical...

(PresseBox) (Hamburg, 20.07.2022) Mindpeak announces the CE-mark for another new product: Mindpeak Breast HER2 RoI (Region of Interest) supports pathologists in the scoring of digital images of breast cancer tissue, which underwent...